Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT)

Michael Wall; Chris A Johnson; Kimberly E Cello; K D Zamba; Michael P McDermott; John L Keltner; NORDIC Idiopathic Intracranial Hypertension Study Group

doi:10.1167/iovs.15-18626

Back

Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT)

Journal article

Open access

Peer reviewed

Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT)

Michael Wall, Chris A Johnson, Kimberly E Cello, K D Zamba, Michael P McDermott, John L Keltner and NORDIC Idiopathic Intracranial Hypertension Study Group

Investigative ophthalmology & visual science, Vol.57(3), pp.805-812

03/2016

DOI: 10.1167/iovs.15-18626

PMCID: PMC4777274

PMID: 26934136

Files and links (1)

url

https://doi.org/10.1167/iovs.15-18626View

Published (Version of record) Open Access

Abstract

The Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) showed that acetazolamide provided a modest, significant improvement in mean deviation (MD). Here, we further analyze visual field changes over the 6-month study period. Of 165 subjects with mild visual loss in the IIHTT, 125 had perimetry at baseline and 6 months. We evaluated pointwise linear regression of visual sensitivity versus time to classify test locations in the worst MD (study) eye as improving or not; pointwise changes from baseline to month 6 in decibels; and clinical consensus of change from baseline to 6 months. The average study eye had 36 of 52 test locations with improving sensitivity over 6 months using pointwise linear regression, but differences between the acetazolamide and placebo groups were not significant. Pointwise results mostly improved in both treatment groups with the magnitude of the mean change within groups greatest and statistically significant around the blind spot and the nasal area, especially in the acetazolamide group. The consensus classification of visual field change from baseline to 6 months in the study eye yielded percentages (acetazolamide, placebo) of 7.2% and 17.5% worse, 35.1% and 31.7% with no change, and 56.1% and 50.8% improved; group differences were not statistically significant. In the IIHTT, compared to the placebo group, the acetazolamide group had a significant pointwise improvement in visual field function, particularly in the nasal and pericecal areas; the latter is likely due to reduction in blind spot size related to improvement in papilledema. (ClinicalTrials.gov number, NCT01003639.).

Pseudotumor Cerebri - drug therapy

Visual Fields - physiology

Follow-Up Studies

Humans

Middle Aged

Pseudotumor Cerebri - diagnosis

Male

Treatment Outcome

Visual Fields - drug effects

Visual Acuity

Pseudotumor Cerebri - physiopathology

Young Adult

Time Factors

Adolescent

Adult

Female

Visual Field Tests

Acetazolamide - therapeutic use

Carbonic Anhydrase Inhibitors - therapeutic use

Details

Title: Subtitle: Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT)
Creators: Michael Wall - Department of Neurology, University of Iowa, Iowa City, Iowa, United States 2Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa, United States
Chris A Johnson - Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa, United States
Kimberly E Cello - Department of Ophthalmology and Vision Science, University of California Davis, Davis, California, United States
K D Zamba - Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, United States
Michael P McDermott - Departments of Biostatistics and Computational Biology and Neurology, University of Rochester Medical Center, Rochester, New York, United States
John L Keltner - Department of Ophthalmology and Vision Science, University of California Davis, Davis, California, United States 6Department of Neurology and Neurological Surgery, University of California Davis, Davis, California, United States
NORDIC Idiopathic Intracranial Hypertension Study Group
Resource Type: Journal article
Publication Details: Investigative ophthalmology & visual science, Vol.57(3), pp.805-812
DOI: 10.1167/iovs.15-18626
PMID: 26934136
PMCID: PMC4777274
NLM abbreviation: Invest Ophthalmol Vis Sci
ISSN: 1552-5783
eISSN: 1552-5783
Publisher: United States
Grant note: U10 EY017281 / NEI NIH HHS 1U10EY017281-01A1 / NEI NIH HHS
Language: English
Date published: 03/2016
Academic Unit: Neurology; Radiology; Biostatistics; Ophthalmology and Visual Sciences
Record Identifier: 9983980047302771

Metrics

25 Record Views

45 Times Cited - Web of Science